{
    "clinical_study": {
        "@rank": "89050", 
        "acronym": "SALTO", 
        "arm_group": [
            {
                "arm_group_label": "Capecitabine", 
                "arm_group_type": "Active Comparator", 
                "description": "Capecitabine 1250 mg/m2 for patients < 70 years of age, and 1000 mg/m2 for patients \u2265 70 years of age, orally b.i.d. day 1-14 with or without bevacizumab 7.5 mg/kg i.v. day 1."
            }, 
            {
                "arm_group_label": "S1", 
                "arm_group_type": "Experimental", 
                "description": "S-1 30 mg/m2 orally b.i.d. irrespective of age, day 1-14 with or without bevacizumab 7.5 mg/kg i.v. day 1."
            }
        ], 
        "brief_summary": {
            "textblock": "The study is a two-arm randomised phase III trial. Patients will be randomised  to receive\n      capecitabine (arm A) or S-1 (arm B). Bevacizumab may be added according to the choice of the\n      investigator. Patients will be followed 3-weekly at the outpatient clinic, toxicity will be\n      assessed according to study protocol guidelines. Patients will be evaluated every 3 cycles\n      for response. Upon disease progression patients will be treated according to the local\n      investigators"
        }, 
        "brief_title": "S-1 Versus Capecitabine in the First Line Treatment of MCC Patients.", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Colorectal Cancer", 
            "Distant Metastases"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Colorectal Neoplasms", 
                "Neoplasm Metastasis"
            ]
        }, 
        "detailed_description": {
            "textblock": "Capecitabine, an oral fluoropyrimidine, has shown a comparable efficacy but a better\n      tolerability compared to bolus 5-FU/LV.  However, capecitabine has a higher incidence of\n      hand-foot syndrome (HFS). HFS is characterized by erythema, dysesthesia and/or paresthesia\n      of the palms of the hands or soles of feet. In advanced stage, desquamation, ulceration and\n      blistering can occur.  Although HFS is not life threatening, it can cause significant\n      discomfort and impairment of function, especially in elderly patients. This adverse event is\n      becoming particularly relevant since many patients may require the administration of\n      capecitabine over prolonged periods of time.\n\n      S-1 (Teysuno\u00ae) is an oral fluoropyrimidine that has shown comparable efficacy to 5FU and\n      capecitabine in gastrointestinal cancers but is associated with a much lower incidence of\n      HFS. Studies on S-1 have mainly been performed in Asian patients,which population has known\n      differences in tumour biology and toxicity compared to Western population. S-1 has shown\n      comparable efficacy to other fluoropyrimidines as monotherapy or in combination chemotherapy\n      schedules in several gastrointestinal tumors. However, given the lack of data from\n      prospective studies on S-1 as monochemotherapy in metastatic colorectal cancer in Western\n      patients, this study is designed to compare S-1 and capecitabine monotherapy in terms of\n      safety, with particular interest in HFS, in metastatic colorectal cancer patients."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histological proof of colorectal cancer.\n\n          -  Distant metastases (patients with only local recurrence are not eligible).\n\n          -  Unidimensionally measurable disease (\u22651 cm on spiral CT scan or \u22652 cm on chest X-ray;\n             liver ultrasound is not allowed). Serum CEA may not be used as a parameter for\n             disease evaluation.\n\n          -  In case of previous radiotherapy, at least one measurable lesion should be located\n             outside the irradiated field.\n\n          -  Age \u2265 18 years\n\n          -  Planned treatment with fluoropyrimidine monotherapy with or without bevacizumab.\n\n          -  WHO performance status 0-2 (Karnofsky PS \u226570%)\n\n          -  Adequate bone marrow function (Hb \u2265 6.0 mmol/L, absolute neutrophil count \u22651.5 x\n             109/L, platelets \u2265 100 x 109/L), renal function (serum creatinine \u2264 1.5x ULN and\n             creatinine clearance, Cockroft formula, \u226530 ml/min), liver function (serum bilirubin\n             \u2264 2 x ULN, serum transaminases \u2264 3 x ULN without presence of liver metastases or \u2264 5x\n             ULN with presence of liver metastases).\n\n          -  Life expectancy > 12 weeks.\n\n          -  Negative pregnancy test in women with childbearing potential.\n\n          -  Expected adequacy of follow-up.\n\n          -  Institutional Review Board approval.\n\n          -  Written informed consent.\n\n        Exclusion Criteria:\n\n          -  Prior adjuvant treatment for stage II/III colorectal cancer completed within 6 months\n             prior to randomisation.\n\n          -  Any prior adjuvant treatment after resection of distant metastases.\n\n          -  Any previous systemic treatment for metastatic disease.\n\n          -  History or clinical signs/symptoms of CNS metastases.\n\n          -  History of a second malignancy <5 years with the exception of adequately treated\n             carcinoma of cervix or basal/squamous cell carcinoma of skin.\n\n          -  Previous intolerance of capecitabine.\n\n          -  Known dihydropyrimidine dehydrogenase (DPD) deficiency or treatment within 4 weeks\n             with DPD inhibitors, including sorivudine or its chemically related analogues such as\n             brivudine.\n\n          -  Planned radical resection of metastases after downsizing by systemic treatment.\n\n          -  Significant cardiovascular disease < 1 yr before randomisation (symptomatic\n             congestive heart failure, myocardial ischemia or infarction, unstable angina\n             pectoris, serious uncontrolled cardiac arrhythmia, arterial thrombosis,\n             cerebrovascular event, pulmonary embolism).\n\n          -  Any significant cardiovascular events during previous fluoropyrimidine therapy."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "160", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 24, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01918852", 
            "org_study_id": "SALTO"
        }, 
        "intervention": [
            {
                "arm_group_label": "Capecitabine", 
                "intervention_name": "Capecitabine", 
                "intervention_type": "Drug", 
                "other_name": "Xeloda"
            }, 
            {
                "arm_group_label": "S1", 
                "intervention_name": "Teysuno", 
                "intervention_type": "Drug", 
                "other_name": "S1"
            }, 
            {
                "arm_group_label": [
                    "Capecitabine", 
                    "S1"
                ], 
                "intervention_name": "Bevacizumab", 
                "intervention_type": "Drug", 
                "other_name": "Avastin"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Capecitabine", 
                "Fluorouracil", 
                "Bevacizumab"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Hand-foot syndrome", 
            "Toxicity", 
            "Fluoropyrimidine", 
            "Capecitabine", 
            "Teysuno", 
            "S1"
        ], 
        "lastchanged_date": "April 18, 2014", 
        "link": {
            "description": "Related Info", 
            "url": "http://www.dccg.nl"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Alkmaar", 
                        "country": "Netherlands"
                    }, 
                    "name": "Medisch Centrum Alkmaar"
                }, 
                "investigator": {
                    "last_name": "M P Hendriks, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Amersfoort", 
                        "country": "Netherlands"
                    }, 
                    "name": "Meander Medisch Centrum"
                }, 
                "investigator": {
                    "last_name": "C. Rodenburg, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Amsterdam", 
                        "country": "Netherlands"
                    }, 
                    "name": "Academic Medical Centre"
                }, 
                "investigator": [
                    {
                        "last_name": "C J Punt, Prof. MD. PhD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "L. Simkens, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Amsterdam", 
                        "country": "Netherlands"
                    }, 
                    "name": "OLVG"
                }, 
                "investigator": {
                    "last_name": "O C Leeksma, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Amsterdam", 
                        "country": "Netherlands"
                    }, 
                    "name": "VUMC"
                }, 
                "investigator": {
                    "last_name": "H. Verheul, Prof. MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "a.cats@nki.nl", 
                    "last_name": "Annemieke Cats, MD PhD"
                }, 
                "facility": {
                    "address": {
                        "city": "Amsterdam", 
                        "country": "Netherlands", 
                        "zip": "1066 CX"
                    }, 
                    "name": "Nederlands Kanker Instituut/Antoni van Leeuwenhoek Ziekenhuis"
                }, 
                "investigator": [
                    {
                        "last_name": "Marcel Verheij, MD PhD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "A. Cats, MD, PhD", 
                        "role": "Principal Investigator"
                    }
                ], 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Assen", 
                        "country": "Netherlands"
                    }, 
                    "name": "Wilhelmina Ziekenhuis"
                }, 
                "investigator": {
                    "last_name": "P J Nieboer, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bergen op Zoom", 
                        "country": "Netherlands"
                    }, 
                    "name": "Ziekenhuis Lievensberg"
                }, 
                "investigator": {
                    "last_name": "M Troost", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Breda", 
                        "country": "Netherlands"
                    }, 
                    "name": "Amphia Ziekenhuis"
                }, 
                "investigator": [
                    {
                        "last_name": "O Loosveld", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "A. ten Tije", 
                        "role": "Principal Investigator"
                    }
                ], 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Doetinchem", 
                        "country": "Netherlands"
                    }, 
                    "name": "Slingeland Ziekenhuis"
                }, 
                "investigator": {
                    "last_name": "E. Muller, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Eindhoven", 
                        "country": "Netherlands"
                    }, 
                    "name": "Catherina Ziekenhuis"
                }, 
                "investigator": {
                    "last_name": "G J Creemers, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Enschede", 
                        "country": "Netherlands"
                    }, 
                    "name": "Medisch Spectrum Twente"
                }, 
                "investigator": {
                    "last_name": "M CJ Legdeur, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Harderwijk", 
                        "country": "Netherlands"
                    }, 
                    "name": "St Jansdal"
                }, 
                "investigator": {
                    "last_name": "M. Temizkan", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hoofddorp", 
                        "country": "Netherlands"
                    }, 
                    "name": "Spaarne Ziekenhuis"
                }, 
                "investigator": {
                    "last_name": "B. de Valk, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Leeuwarden", 
                        "country": "Netherlands"
                    }, 
                    "name": "Medisch Centrum Leeuwarden"
                }, 
                "investigator": {
                    "last_name": "M.B. Polee", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nieuwegein", 
                        "country": "Netherlands"
                    }, 
                    "name": "Antonius Ziekenhuis"
                }, 
                "investigator": {
                    "last_name": "M Los", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Purmerend", 
                        "country": "Netherlands"
                    }, 
                    "name": "Waterland Ziekenhuis"
                }, 
                "investigator": {
                    "last_name": "J. A.C Brakenhof, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rotterdam", 
                        "country": "Netherlands"
                    }, 
                    "name": "Sint Franciscus Gasthuis"
                }, 
                "investigator": {
                    "last_name": "P. Hamberg, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Schiedam", 
                        "country": "Netherlands"
                    }, 
                    "name": "Vlietland Ziekenhuis"
                }, 
                "investigator": {
                    "last_name": "J Ruit, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sittard", 
                        "country": "Netherlands"
                    }, 
                    "name": "Orbis Medisch Centrum"
                }, 
                "investigator": {
                    "last_name": "F.L.G. Erdkamp, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tilburg", 
                        "country": "Netherlands"
                    }, 
                    "name": "Tweesteden Ziekenhuis"
                }, 
                "investigator": {
                    "last_name": "S Goey, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Utrecht", 
                        "country": "Netherlands"
                    }, 
                    "name": "University Medical Centre Utrecht"
                }, 
                "investigator": [
                    {
                        "last_name": "M Koopman, MD, PhD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "W MU van Grevenstein, MD, PhD", 
                        "role": "Principal Investigator"
                    }
                ], 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Venlo", 
                        "country": "Netherlands"
                    }, 
                    "name": "VieCuri Medisch Centrum"
                }, 
                "investigator": {
                    "last_name": "Y van de Wouw, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Zaandam", 
                        "country": "Netherlands"
                    }, 
                    "name": "Zaans Medisch Centrum"
                }, 
                "investigator": {
                    "last_name": "A Bochove", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "Netherlands"
        }, 
        "number_of_arms": "2", 
        "official_title": "S1 Versus Capecitabine in the First Line Treatment of Metastatic Colorectal Cancer Patients, the SALTO Randomised Phase III Study of the Dutch Colorectal Cancer Group. A Safety Evaluation of Oral Fluoropyrimidines", 
        "overall_contact": {
            "email": "l.mol@iknl.nl", 
            "last_name": "Linda Mol, MSc", 
            "phone": "+31 243616837"
        }, 
        "overall_official": {
            "affiliation": "Amsterdam Medical Centre", 
            "last_name": "Cornelis JA Punt, Prof. MD. PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To determine the incidence of HFS in first line treatment with S-1 compared to capecitabine in patients with metastatic colorectal cancer.", 
            "measure": "Incidence of HFS in first line treatment", 
            "safety_issue": "Yes", 
            "time_frame": "HFS will be assessed every 3 weeks up to 6 months average."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01918852"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Incidence of grade 3 hand-foot syndrome, according to CTC 4.0.", 
                "measure": "Grade 3 HFS", 
                "safety_issue": "Yes", 
                "time_frame": "HFS will be assessed every 3 weeks, up to 6 months average"
            }, 
            {
                "description": "Time from randomisation until progression or death whichever comes first", 
                "measure": "Progression-free survival", 
                "safety_issue": "No", 
                "time_frame": "Every 9 weeks, for 6 months (average)"
            }, 
            {
                "description": "Adverse events graded accoording to the NCI CTCAE version 4", 
                "measure": "Overall toxicity", 
                "safety_issue": "Yes", 
                "time_frame": "Every 3 weeks, for 6 months (average)"
            }, 
            {
                "description": "From date of randomisation to death or last known to be alive", 
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "Response acccording to RECIST 1.1", 
                "measure": "Response rate", 
                "safety_issue": "No", 
                "time_frame": "Response will be assessed every 9 weeks, up to 6 months average."
            }
        ], 
        "source": "Dutch Colorectal Cancer Group", 
        "sponsors": {
            "collaborator": {
                "agency": "Nordic Pharma SAS", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Dutch Colorectal Cancer Group", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}